Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Latest Information Update: 29 May 2025
At a glance
- Drugs MNPR-101-Zr (Primary)
- Indications Colorectal cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus First in man; Pharmacokinetics
- Sponsors Monopar Therapeutics
Most Recent Events
- 22 May 2025 Planned End Date changed from 1 Jun 2025 to 1 Apr 2026.
- 22 May 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Apr 2026.
- 22 Oct 2024 According to a Monopar Therapeutics media release, company is presenting today , MNPR-101-Zr clinical development program details at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress held in Hamburg.